Erlotinib – USA

Erlotinib – USA

IPR decision:

AIA Review
Filing Date
Institution Date
Petitioner
Patent No.
Status
IPR2016-01284
06/28/2016
01/09/2017
Apotex, Inc
US 6,900,221
Final Written Decision (Claims 44‒46 and 53 are Unpatentable)

PTAB concluded that Petitioner has demonstrated that the preponderance of the evidence of record supports that it would have been obvious to the ordinary artisan at the time of invention to combine Schnur with either OSI’s 10-K or Gibbs, with a reasonable expectation of success.
Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved